Clinical Trials
38 trialsBrentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
RADAR
University College, London
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
M.D. Anderson Cancer Center
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
St. Jude Children's Research Hospital
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
National Medical Research Radiological Centre of the Ministry of Health of Russia
BrECADD
University of Miami
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Fondazione Italiana Linfomi - ETS
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
University of Washington
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
City of Hope Medical Center
HL-Russia-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
University College, London
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Northwestern University
BREACH
The Lymphoma Academic Research Organisation
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
Fondazione Michelangelo
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
HD16
University of Cologne
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Massachusetts General Hospital
HD17 for Intermediate Stage Hodgkin Lymphoma
University of Cologne
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
Martin-Luther-Universität Halle-Wittenberg
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Martin-Luther-Universität Halle-Wittenberg
(Optimist)
King Abdullah International Medical Research Center
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
M.D. Anderson Cancer Center
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
University of Cologne
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AVD-Rev
University of Cologne
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Massachusetts General Hospital
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
French Innovative Leukemia Organisation
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
Fondazione Michelangelo
Rituximab and ABVD for Hodgkin's Patients
M.D. Anderson Cancer Center
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
M.D. Anderson Cancer Center
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease
American Scitech International
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
American Scitech International